NLPHL | LRCHL | T/HRBCL | |
Clinical presentation | 53 percent Stage I | 46 percent Stage I | 8 percent Stage I |
28 percent Stage II | 24 percent Stage II | 8 percent Stage II | |
14 percent Stage III | 24 percent Stage III | 15 percent Stage III | |
6 percent Stage IV | 6 percent Stage IV | 69 percent Stage IV | |
10 percent B symptoms | 10 percent B symptoms | 54 percent B symptoms | |
Neoplastic cells | L&H cell | Reed-Sternberg cell which can resemble L&H cells or lacunar cells | Can resemble the L&H cell, centroblast, immunoblast, or Reed-Sternberg cell |
Background cells | B cells >T cells small B cells, CD3+CD4+CD57+ T cells and follicular dendritic cells | Variable. In nodular cases, Reed-Sternberg cells may be found adjacent to B cell follicles | T cells >B cells CD8+ cytotoxic T cells and histiocytes |
Growth pattern | Nodular, at least in part | Usually nodular but can be diffuse | Usually diffuse |
Tumor cell immunophenotype | |||
CD15 | - | + | - |
CD30 | -/+ | +/- | -/+ |
CD20 | + | -/+ | + |
CD45 | + | - | + |
EMA | +/- | - | +/- |
BOB-1 | + | -/+ | + |
OCT-2 | + | -/+ | + |
BLC6 | + | -/+ | +/- |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟